The investment round was led by FoundersX with participation from Founders Factory, Y Combinator, and Plug and Play Ventures.
"This is a massive achievement for us. When we came to market 2 years ago we were probably the only technology company talking about fairness and diversity. Fairness has been our core purpose from day one, it’s in our DNA, and we are so grateful to our investors and clients who saw how important our message was. For me this represents an investment in diversity, not just our company. This latest round will allow us to grow our capability in our core markets, levelling the playing field and breaking the cycle of exclusion that still chronically prevalent in the world of work. It is also a huge vote of confidence in the team who have worked so hard over the past 2 years to bring our purpose to life."
The funding round was led by Downing Ventures and Gresham House Ventures to accelerate the rollout of white label lending solutions for banks.
"We are delighted that Downing and Gresham House have joined us on our exciting journey to help reshape a sector that is rapidly adopting digital solutions using new data sources to enable the delivery of seamless, instant access to finance. This is creating the opportunity to provide small businesses with the same transparency and ease of access to finance that consumers have become accustomed to."
The £2m injection brings Adarga's total Series A fundraising to £7m following previous backing led by Allectus Capital.
"We are pleased to be investing in Adarga and look forward to supporting the Adarga team as it continues to build out its software products adarga_engine™ and adarga_bench™."
YFM Equity Partners has backed enterprise software provider SharpCloud in a Series A round to support international expansion and product development.
"We're really excited to have found and partnered with an investor, in YFM, that understands and shares our vision. This round of funding comes at a time where we have begun to experience rapid growth, with the SharpCloud product continually garnering rave reviews and subsequent viral effects taking hold. We're now able to capitalise on the huge opportunity that lies ahead. We have built a great relationship with Adam and Jamie during the process and have enjoyed their straight-forward and pragmatic approach. We're delighted to have YFM join the team."
Epidarex Capital and the University of Leeds led the Series A round to support the development of next generation anticoagulants.
"There is an urgent need for anticoagulant therapies with reduced bleeding risk. Our research has validated that targeting activated Factor XII may lead to differentiated therapies and a new treatment option for patients."
